3rd Peptide-Based Therapeutics Summit 2026

Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.

To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.

Gathering industry leaders including Parabilis Medicines, Circle Pharma, Abbvie, Merck, Chugai Pharmaceuticals and many more, this is your premium forum to explore:

• Novel computational tools
• Optimize analytical assays
• Formulating cell-specific delivery methods
• DMPK translatability towards clinical success of peptide therapies

With the likes of Alnylam, Pfizer, MIT, Rapafusyn Pharma, a stealth start-up and more already booked on to join, be part of 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.

For more information, click here.